photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer Medical Treatment


Davendra P.S. Sohal, Pamela B. Mangu, Alok A. Khorana, Manish A. Shah, Philip A. Philip, Eileen M. O’Reilly, Hope E. Uronis, Ramesh K. Ramanathan, Christopher H. Crane, Anitra Engebretson, Joseph T. Ruggiero, Mehmet S. Copur, Michelle Lau, Susan Urba and Daniel Laheru ABSTRACT Purpose: To provide evidence-based recommendations to oncologists and others for the treatment […]

Share Button

“Modified” FOLFIRINOX Regimen Approved by FDA for 2nd Line Treatment of Pancreatic Cancer

On the 22nd of October, 2015, the U.S. Food and Drug Administration approved a new combination therapy that includes the drug Onivyde for patients with metastatic pancreatic cancer who had earlier been treated until progression of disease while on gemcitabine or a gemcitabine-based regimen. Onivyde is liposomal irinotecan, a topoisomerase I inhibitor (was called CPT-11, […]

Share Button

Clinical trial of Combination of Targeted Anti-Kras Therapy for Pancreatic Cancer

Dutch and primarily other European researchers are about to begin a human clinical trial involving a regimen of two relatively new targeted therapies (afatinib plus selumetinib) for the treatment of pancreatic cancer.  Afatinib is known as Gilotrif in the U.S., and is produced by the family-owned global but German-headquartered Boehringer Ingelheim Pharmaceuticals firm.  Selumetinib is […]

Share Button
Page 1 of 812345...Last »